STOCKS TELEGRAPH

Tag: CADL Stock

  • Candel (CADL) Stock Skyrockets Following Major Clinical Trial Milestone

    Candel (CADL) Stock Skyrockets Following Major Clinical Trial Milestone

    With the release of encouraging primary endpoint findings from its phase 3 clinical study assessing CAN-2409 viral immunotherapy in localized prostate cancer, Candel Therapeutics, Inc. (NASDAQ: CADL) has reached a noteworthy milestone. The shares of CADL jumped 144.61% after this statement, trading at $11.28 as of the latest market check.

    A landmark Results of the Phase 3 Trial

    In this phase 3 trial, which was randomized, double-blind, and placebo-controlled, 745 individuals with intermediate-to-high-risk, localized prostate cancer were included. When CAN-2409 was used in conjunction with valacyclovir and usual treatment, the experiment showed a statistically significant increase in disease-free survival (DFS).

    This combination outperformed standard care alone. To further assess the safety and efficacy of short-term androgen deprivation therapy (ADT), the patients were stratified. A significant breakthrough in localized prostate cancer treatment, the study’s main goal highlights CAN-2409’s potential to improve patient outcomes without causing significant harm.

    A Novel Viral Immunotherapy, CAN-2409

    The herpes simplex virus thymidine kinase (HSV-tk) gene is delivered directly to tumor cells by the replication-defective, experimental adenovirus CAN-2409. When used in conjunction with valacyclovir, this treatment destroys immunogenic cells and stimulates the tumor microenvironment, which results in a customized CD8+ T cell-mediated defense against tumor antigens.

    This novel method targets a wide range of tumor antigens and functions as an in situ vaccination. Evidence from preclinical and clinical studies suggests that CAN-2409 synergizes effectively with localized radiotherapy, further validating its role in the trial’s success.

    Treatment Implications for Prostate Cancer

    In the US, more than 100,000 men are affected by localized prostate cancer each year, and more than 50,000 of them need radiation treatment. In the United States alone, the addressable market for CAN-2409 is estimated to be worth over $10 billion.

    Candel plans to talk with the FDA about regulatory options in light of the encouraging study findings. CADL plans to present comprehensive data at forthcoming medical conferences. If approved, CAN-2409 could revolutionize prostate cancer treatment, providing patients with an effective option to reduce recurrence risk and improve long-term outcomes.

  • Candel Therapeutics (CADL) Rockets Skyward with Breakthrough Pancreatic Cancer Study Results

    Thursday witnessed an unprecedented surge in market enthusiasm as Candel Therapeutics, Inc. (NASDAQ: CADL) stunned investors with a monumental leap of nearly 280%, soaring from $1.68 to $6.40. Yet, the spectacle continued in the aftermarket trading hours, with CADL’s price rocketing further by a staggering 9%.

    This whirlwind of activity underscores the intense fervor surrounding the company, evidenced by an extraordinary volume of over 142 million shares changing hands, a stark contrast to the typical daily average of a mere 80,000 shares.

    Pancreatic Cancer Study Results

    Fueling this meteoric rise is the revelation of profoundly positive outcomes from Candel Therapeutics’ groundbreaking pancreatic cancer study. Positioned as a leading biotechnology firm specializing in late-stage viral immunotherapies, the company’s latest triumph underscores its unwavering commitment to pioneering advancements in cancer treatment.

    Unveiling updated interim survival data from its ongoing phase 2 trial of CAN-2409, an immunotherapy of considerable promise, in conjunction with valacyclovir and standard chemoradiation, Candel Therapeutics unveiled an array of compelling findings. Presented at the esteemed 2023 Society for Immunotherapy Annual Meeting, these results showcased:

    • A striking median overall survival period of 28.8 months within the CAN-2409 cohort, a stark contrast to the 12.5 months observed in the control group.
    • Encouraging survival rates of 71.4% and 47.6% at the 24 and 36-month milestones respectively among patients treated with CAN-2409.
    • Of particular note, 4 out of 7 patients administered CAN-2409 were still alive at the data cut-off, with two surpassing the remarkable milestone of 50 months since enrollment.
    • Significantly, Candel Therapeutics’ immunotherapy elicited a robust activation of the immune response, evidenced by consistent findings in both blood and resected tumors.

    Conclusion

    Candel Therapeutics’ triumphant strides represent a significant breakthrough in the relentless battle against pancreatic cancer. The company’s steadfast dedication to pushing the boundaries of medical science not only ignites hope for future patients but also yields substantial value for CADL shareholders.

    Pioneering the frontier as the first to unveil such promising data, Candel Therapeutics establishes a formidable precedent for the transformative potential of immunotherapy in cancer treatment. With continued momentum and a promising safety profile, CADL stands poised to redefine the landscape of oncological therapeutics, embarking on a trajectory of profound impact and innovation.